NY-ESO-1 Specific TCR-Engineered T Cell Immunotherapy for Triple Negative Breast Cancer
Abstract
The purpose of this award will be to address the overarching challenge of eliminating mortality associated with metastatic breast cancer, specifically, the subtype, TNBC. We hypothesize that treatment of TNBC patients with NY-ESO-1 TCR-transduced T cells is safe and will result in tumor regression and clinical benefits. We further hypothesize that maximal therapeutic immunity could be achieved by improving T cell persistence and trafficking of A2-ESO-1 TCR engineered T cells, as well as critical help and cytotopic function of DP4-ESO-1 TCR-transduced CD4+ T cells. Importantly, such an antitumor immunity could be further amplified in vivo by blocking immune suppression.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2023
- Accession Number
- AD1209087
Entities
People
- Jenny Chang
Organizations
- Houston Methodist Research Institute